Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , March 17, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted a stock option to purchase 151,200 shares of Karyopharm’s common
View HTML
Toggle Summary Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer
NEWTON, Mass. , March 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of John Demaree as Chief Commercial Officer. In this role, Mr. Demaree will lead Karyopharm’s commercial strategy and
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , March 09, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 119,500 shares of
View HTML
Toggle Summary Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
NEWTON, Mass. , March 06, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the closing of its previously announced registered underwritten public offering and the exercise in full of the underwriters’ option to purchase
View HTML
Toggle Summary Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
NEWTON, Mass. , March 03, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the pricing of its previously announced registered underwritten public offering of 6,250,000 shares of its common stock  at a price to the
View HTML
Toggle Summary Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock
NEWTON, Mass. , March 02, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the commencement of a registered underwritten public offering of $150 million in shares of its common stock.
View HTML
Toggle Summary Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy
− Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) plus Dexamethasone ( SVd) Results in Statistically Significant Reduction in the Risk of Disease Progression or Death Compared to Standard Twice-Weekly Velcade® plus Dexamethasone (Vd) Regimen  − − 47% Increase in
View HTML
Toggle Summary Karyopharm Appoints Richard Paulson to its Board of Directors
Current Executive Vice President and Chief Executive Officer of Ipsen North America, and former Vice President and General Manager of Oncology at Amgen, Inc.; Brings Wealth of Leadership and Global Strategic Experience NEWTON, Mass. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc.
View HTML
Toggle Summary U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (Selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Priority Review Granted; User Fee Goal Date Set for June 23, 2020 NEWTON, Mass. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for filing its
View HTML
Toggle Summary Karyopharm to Participate at 9th Annual SVB Leerink Global Healthcare Conference
− Fireside Chat Scheduled for Tuesday, February 25, 2020, at 11:30 a.m. ET − NEWTON, Mass. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will
View HTML